Aetna CO-197 Prior Auth Denials in Dermatology
Precertification / authorization / notification absent. Real-world appeal strategy, filing deadlines, and copy-paste letter template for Aetna dermatology claims.
Verify before filing
Filing deadlines, appeal addresses, and policy criteria described here reflect typical payer behavior at publication. Aetna updates policies frequently and plan-level rules vary by employer group, state, and line of business. Always cross-check the specific deadline and filing address on your EOB, and confirm current Aetna medical-policy language through the provider portal before submitting an appeal.
Why Aetna throws CO-197 for dermatology
Understanding the specific combination of payer policy, specialty workflow, and CARC mechanics is what separates an easy fix from an endless appeal loop.
Aetna dermatology prior-auth centers on two high-cost categories: biologic drugs and Mohs micrographic surgery outside standard coverage zones. Biologics (Dupixent 96377, Cosentyx, Skyrizi, Tremfya, Stelara) require prior authorization plus failed conventional therapy documentation. Mohs surgery (17311, 17313, 17315) is covered without auth on head, neck, hands, feet, and genitalia, but requires prior auth everywhere else.
The CO-197 denial in Aetna dermatology typically fires when a biologic is injected in-office before the auth approval lands, or when Mohs is performed on the trunk/extremities without first obtaining auth. Aetna's CPB for biologics is strict: most require 12 weeks of topical steroids or phototherapy failure before approval. Mohs auth outside head/neck requires documented positive margins on prior excision or a specific high-risk feature (size over 2cm, poorly-differentiated pathology, recurrent lesion, immunosuppressed patient).
Step-therapy failures are the biggest documentation gap. If the auth request did not include specific drug names, doses, durations, and response/failure notes for conventional therapies, Aetna will deny on CPB criteria and the subsequent claim CO-197s.
Aetna leans hard on prior-authorization audits and medical-necessity denials against clinical policy bulletins (CPBs). Precertification gaps and CPB-based medical-necessity denials dominate their recoverable denial volume.
Availity is Aetna's primary claim-status and corrected-claim portal. Appeals route through the Aetna provider website or the Availity dispute workflow.
- Level 1 reconsideration via Availity dispute
- Formal written appeal to Aetna Provider Resolution Unit (PO Box 14463, Lexington KY)
- Peer-to-peer clinical review (request within 14 days of adverse determination)
- External review / state insurance department complaint (last resort)
Dermatology coverage-policy gotchas
Dermatology denials cluster around cosmetic vs medical boundary questions, biologic-drug prior-auth, and Mohs surgery coverage criteria.
Biologics (Dupixent, Cosentyx, Skyrizi) require prior-auth with failed conventional therapy documentation at every commercial payer. Mohs surgery outside head/neck/hands/feet triggers medical-necessity review. Cosmetic-adjacent procedures (like Botox for hyperhidrosis) need precise ICD-10 and documentation to survive CO-204 denials.
Exact fix: step by step
Specific, actionable workflow. Not theory. What to pull, what to attach, where to file.
For biologics CO-197: check whether the auth request included the complete step-therapy documentation. If yes and the auth was still denied, appeal with the treating dermatologist's statement on why conventional therapy is contraindicated or has failed. If no, file retro-auth with the complete documentation (topical steroid trial dates and doses, phototherapy dates and number of sessions, any prior biologic trials and reasons for discontinuation).
For Mohs outside head/neck/hands/feet: the appeal needs pathology from the biopsy showing a high-risk feature. Attach the biopsy report, a diagram of the lesion location and size, and a clinical note explaining why standard excision is not appropriate (cosmetically sensitive area, recurrent lesion, immunosuppressed patient).
Peer-to-peer review is the fastest escalation for both cases. Aetna's dermatology UM reviewers are typically dermatologists themselves and respond well to clinical nuance from the treating physician.
Aetna filing deadline
- Formal appeal180 days
- Corrected claim120 days
- Peer-to-peerWithin 14 days
Aetna's 180-day appeal window applies. Retro-auth for biologics should be filed within 30 days; after that, the medical director typically requires formal appeal. Mohs retro-auth is more flexible. Up to 60 days with complete documentation.
Copy-paste appeal letter
Specialty-tuned template with placeholder fields. Swap in your patient details, dates, and clinical specifics. Attach the documentation listed at the bottom of the letter.
[Practice Letterhead] [Date] Aetna Provider Resolution Unit PO Box 14463 Lexington, KY 40512 Re: Appeal of CO-197 Denial Member: [Patient Name] Member ID: [Member ID] Date of Service: [DOS] Claim Number: [Claim #] CPT: [e.g., 96377 - Biologic injection; or 17311 - Mohs first stage] To Whom It May Concern: We are appealing the CO-197 prior-authorization denial for the above-referenced dermatology service. The service was medically necessary and meets the criteria established in Aetna CPB [number]. Clinical Indication: [Biologic case:] Patient with [condition, e.g., moderate-to-severe atopic dermatitis, psoriasis] has failed [X weeks] of conventional therapy including: - [Topical steroid name, potency, duration, response] - [Phototherapy: UVB/PUVA, number of sessions, response] - [Prior biologic trial if applicable] [Mohs case:] Patient has a biopsy-confirmed [pathology, e.g., BCC, SCC] located at [body site]. Clinical features indicating Mohs necessity include [size X cm, location rationale, histologic subtype, recurrent/immunosuppressed]. Documentation attached: 1. Treating dermatologist H&P 2. Step-therapy / failed conservative care documentation 3. [For Mohs] Biopsy pathology report 4. Retroactive authorization request filed [date] 5. Aetna CPB [number] criteria worksheet We respectfully request approval and reprocessing. [Dr. Name] is available for peer-to-peer at [phone]. Sincerely, [Name]
Every bracketed field in the template is a data point or document you must provide. Missing any of these is the single largest cause of appeal denials. Build a pre-filing checklist from the “Documentation attached” section of the letter above.
High-risk CPTs for this combo
These CPT codes trigger CO-197 denials at Aetna most frequently in dermatology claims. Watch them in your denial dashboard.
Get a free AR denial audit of your dermatology claims.
Upload your denial export. Our AI classifies every CO-197, CO-50, CO-97, CO-16, and CO-204 line by root cause, then surfaces which ones are actually recoverable. AAPC-certified review. Written report in your inbox. Usually inside an hour.
Common questions on this scenario
What does CO-197 mean when Aetna denies a dermatology claim?
CO-197 is a CARC denial for precertification / authorization / notification absent. In Dermatology practice with Aetna, this typically fires on 96377, 17311, 17313 and similar high-risk CPTs.
What is Aetna's filing deadline for CO-197 appeals?
Aetna's 180-day appeal window applies. Retro-auth for biologics should be filed within 30 days; after that, the medical director typically requires formal appeal. Mohs retro-auth is more flexible. Up to 60 days with complete documentation.
What is the typical overturn rate for CO-197 appeals in dermatology?
55-70 percent for biologics; 75-85 percent for Mohs with pathology. Success depends heavily on documentation quality and whether clinical criteria in Aetna's medical policy are matched point-by-point.
Can I file a corrected claim or must I file a formal appeal?
Start with corrected claim if the fix is administrative (wrong modifier, auth number mismatch). File formal appeal when clinical medical necessity is the dispute.
Sources and review
What this guide is based on
- Aetna public provider manual and medical-policy library
- X12 CARC / RARC code set (maintained by the ASC X12 committee)
- CMS Local Coverage Determinations and National Coverage Determinations database
- MGMA, HFMA, and Change Healthcare denial-rate benchmarks for industry context
- AAPC-credentialed coder review of appeal-strategy guidance
What you should verify yourself
Overturn-rate ranges reflect typical patterns and AAPC reviewer consensus, not payer-published statistics. Filing deadlines and appeal addresses vary by plan, state, and employer group. Always confirm on the EOB for the specific claim and on the payer’s current provider portal before filing.
This content is provided for educational and informational purposes only. It is not legal, clinical, or coding advice. Go Medical Billing LLC makes no guarantee of appeal outcomes; overturn rates depend on the specific claim, documentation, and payer-plan combination.
Stop losing revenue to CO-197 denials
We audit dermatology practices' Aetna denials and recover what your team is writing off. Free audit. AAPC-certified coders. 2.49 percent of collections.